Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Breast cancer stem cells: A review of their characteristics and the agents that affect them.

Tytuł :
Breast cancer stem cells: A review of their characteristics and the agents that affect them.
Autorzy :
Shan NL; Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, USA.
Shin Y; Yonsei University, College of Medicine, Seoul, Republic of Korea.
Yang G; Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, USA.
Furmanski P; Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, USA.; Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
Suh N; Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, USA.; Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
Pokaż więcej
Źródło :
Molecular carcinogenesis [Mol Carcinog] 2021 Feb; Vol. 60 (2), pp. 73-100. Date of Electronic Publication: 2021 Jan 11.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
Język :
English
Imprint Name(s) :
Publication: <2005- > : [Hoboken, N.J.] : Wiley-Liss
Original Publication: New York : Alan R. Liss, Inc., c1988-
MeSH Terms :
Gene Expression Regulation, Neoplastic*
Breast Neoplasms/*genetics
Drug Resistance, Neoplasm/*genetics
Neoplastic Stem Cells/*metabolism
Signal Transduction/*genetics
Transcription Factors/*genetics
Antineoplastic Agents/therapeutic use ; Breast Neoplasms/drug therapy ; Breast Neoplasms/metabolism ; Cell Self Renewal/genetics ; Drug Resistance, Neoplasm/drug effects ; Humans ; Molecular Targeted Therapy/methods ; Neoplastic Stem Cells/drug effects ; Neoplastic Stem Cells/pathology ; Signal Transduction/drug effects ; Transcription Factors/metabolism
References :
Oncogene. 2012 May 24;31(21):2614-26. (PMID: 21996747)
Oncotarget. 2017 Jan 3;8(1):1913-1924. (PMID: 27765921)
J Dig Dis. 2014 Apr;15(4):159-65. (PMID: 24373518)
J Cell Biochem. 2018 Sep 6;:. (PMID: 30191610)
Onco Targets Ther. 2015 Dec 16;8:3783-92. (PMID: 26719706)
Nat Rev Cancer. 2014 Nov;14(11):736-46. (PMID: 25342631)
Integr Cancer Ther. 2019 Jan-Dec;18:1534735419866908. (PMID: 31416372)
Nat Commun. 2019 Aug 14;10(1):3668. (PMID: 31413316)
Biomed Pharmacother. 2020 Mar;123:109778. (PMID: 31855735)
Mol Cancer. 2018 Feb 19;17(1):34. (PMID: 29455658)
J Transl Med. 2011 Dec 07;9:209. (PMID: 22152097)
Int J Oncol. 2018 Jul;53(1):339-348. (PMID: 29750424)
Cell Commun Signal. 2020 Feb 28;18(1):33. (PMID: 32111215)
Cell Rep. 2019 Jan 15;26(3):624-638.e8. (PMID: 30650356)
Cancer Biol Ther. 2016 Jun 2;17(6):698-707. (PMID: 27259361)
Drug Metab Dispos. 2018 May;46(5):567-580. (PMID: 29514827)
Redox Biol. 2018 Jul;17:246-258. (PMID: 29729523)
Iran Biomed J. 2018 Sep 17;23(3):184-9. (PMID: 30220190)
Biomolecules. 2017 Jul 11;7(3):. (PMID: 28696357)
Cold Spring Harb Perspect Med. 2016 Oct 3;6(10):. (PMID: 27599530)
Cell. 2008 May 16;133(4):704-15. (PMID: 18485877)
Breast Cancer Res Treat. 2018 May;169(1):47-57. (PMID: 29350308)
Breast Cancer Res Treat. 2016 May;157(1):77-90. (PMID: 27120467)
Stem Cell Res. 2019 Oct;40:101538. (PMID: 31450192)
Oncogene. 2014 Nov 20;33(47):5477-82. (PMID: 24317509)
Curr Osteoporos Rep. 2012 Jun;10(2):151-9. (PMID: 22544628)
Nat Med. 2014 Jan;20(1):14-5. (PMID: 24398956)
Onco Targets Ther. 2015 Dec 23;9:49-59. (PMID: 26730203)
Cancer Microenviron. 2018 Dec;11(2-3):141-152. (PMID: 30255421)
Cancer Biomark. 2017;18(1):69-76. (PMID: 27814277)
FEBS J. 2017 Jun;284(12):1830-1854. (PMID: 28398698)
Stem Cells. 2015 Oct;33(10):2913-24. (PMID: 26086949)
Nat Rev Mol Cell Biol. 2013 Jul;14(7):416-29. (PMID: 23719536)
J Clin Invest. 2012 Jun;122(6):2066-78. (PMID: 22585577)
Oncotarget. 2018 May 4;9(34):23519-23531. (PMID: 29805752)
Anticancer Res. 2017 Jan;37(1):35-46. (PMID: 28011471)
J Exp Clin Cancer Res. 2018 Oct 19;37(1):256. (PMID: 30340507)
Genes (Basel). 2019 Oct 12;10(10):. (PMID: 31614829)
Oncogene. 2017 Mar 30;36(13):1862-1872. (PMID: 27721402)
Cancer Treat Rev. 2018 Sep;69:152-163. (PMID: 30029203)
Mol Med Rep. 2019 May;19(5):3667-3675. (PMID: 30896795)
Arch Toxicol. 2017 Mar;91(3):1261-1278. (PMID: 27358235)
Lab Anim Res. 2011 Jun;27(2):147-52. (PMID: 21826175)
Biomedicines. 2018 Jul 17;6(3):. (PMID: 30018256)
Breast Cancer Res Treat. 2014 Jun;145(3):593-604. (PMID: 24810497)
Cancer Res. 2016 Oct 1;76(19):5857-5869. (PMID: 27480274)
Cell Stem Cell. 2012 Apr 6;10(4):440-54. (PMID: 22482508)
Cell. 2006 Aug 25;126(4):663-76. (PMID: 16904174)
Oncogene. 2014 May 15;33(20):2655-64. (PMID: 23770853)
Stem Cells. 2008 Feb;26(2):364-71. (PMID: 17975224)
Nutrients. 2018 Jun 15;10(6):. (PMID: 29914089)
J Biol Chem. 2015 Mar 13;290(11):6857-67. (PMID: 25605728)
Clin Cancer Res. 2013 Dec 1;19(23):6520-31. (PMID: 24141629)
PLoS One. 2015 Feb 06;10(2):e0117097. (PMID: 25658419)
Cancer Res. 2017 Dec 1;77(23):6641-6650. (PMID: 28951456)
Biochem Pharmacol. 2011 May 1;81(9):1124-35. (PMID: 21371442)
Oncogene. 2009 Aug 13;28(32):2894-902. (PMID: 19503094)
Cancers (Basel). 2015 Aug 11;7(3):1554-85. (PMID: 26270676)
Life Sci. 2018 Mar 1;196:56-62. (PMID: 29355544)
Cell Rep. 2015 Sep 29;12(12):1968-77. (PMID: 26387946)
Cancer Lett. 2018 Jun 1;423:47-59. (PMID: 29496539)
J Cancer Prev. 2016 Dec;21(4):235-242. (PMID: 28053957)
Biomed Pharmacother. 2019 Jun;114:108800. (PMID: 30921705)
Onco Targets Ther. 2011;4:71-8. (PMID: 21792314)
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8. (PMID: 12629218)
Am J Stem Cells. 2013 Mar 08;2(1):52-61. (PMID: 23671816)
Mol Cancer. 2017 Feb 16;16(1):41. (PMID: 28209166)
Cancer Res. 2010 Jan 15;70(2):709-18. (PMID: 20068161)
Carcinogenesis. 2018 Dec 31;39(12):1488-1496. (PMID: 30321288)
Mol Cell Biochem. 2015 Nov;409(1-2):163-76. (PMID: 26187676)
Cancer Res. 2008 Apr 1;68(7):2419-26. (PMID: 18381450)
Nat Rev Clin Oncol. 2020 Jan;17(1):33-48. (PMID: 31548601)
Circ Res. 2014 Jul 7;115(2):311-24. (PMID: 24989490)
Oncotarget. 2018 Nov 23;9(92):36515-36529. (PMID: 30559934)
Int J Oncol. 2018 Jul;53(1):47-58. (PMID: 29749438)
Oncol Lett. 2015 Dec;10(6):3443-3449. (PMID: 26788148)
Cancer Res Treat. 2017 Oct;49(4):869-879. (PMID: 28052658)
Breast Cancer Res Treat. 2012 May;133(1):75-87. (PMID: 21818590)
Oncogene. 2019 Apr;38(17):3151-3169. (PMID: 30622340)
Oncogene. 2011 May 5;30(18):2161-72. (PMID: 21242971)
Clin Sci (Lond). 2015 Nov;129(9):809-22. (PMID: 26201092)
Cell Metab. 2017 Oct 3;26(4):633-647.e7. (PMID: 28978427)
Mol Pharmacol. 2011 Mar;79(3):360-7. (PMID: 21115634)
Oncotarget. 2017 Jul 4;8(27):44917-44943. (PMID: 28388544)
Nat Commun. 2018 Sep 19;9(1):3815. (PMID: 30232459)
Stem Cell Reports. 2013 Dec 27;2(1):78-91. (PMID: 24511467)
Nat Med. 1997 Jul;3(7):730-7. (PMID: 9212098)
Stem Cells. 2014 Nov;32(11):2858-68. (PMID: 25070049)
Oncotarget. 2017 Jul 25;8(30):49110-49122. (PMID: 28418877)
Cancer Cell Int. 2020 Feb 14;20:51. (PMID: 32082081)
Mol Cancer Ther. 2019 Dec;18(12):2220-2232. (PMID: 31451564)
Bioimpacts. 2016;6(2):105-10. (PMID: 27525228)
EMBO Rep. 2014 Mar;15(3):244-53. (PMID: 24531722)
Mol Med Rep. 2018 Feb;17(2):3397-3403. (PMID: 29257278)
J Anal Sci Technol. 2015;6(1):28. (PMID: 26495157)
J Biol Chem. 2008 Jun 20;283(25):17635-51. (PMID: 18441325)
Theranostics. 2020 Jan 19;10(5):2405-2421. (PMID: 32104513)
Int J Cancer. 2017 Oct 1;141(7):1402-1412. (PMID: 28614911)
Cell Rep. 2015 Nov 3;13(5):1046-58. (PMID: 26565916)
Front Cell Dev Biol. 2017 Feb 03;5:7. (PMID: 28217689)
Stem Cells Int. 2018 Feb 28;2018:5416923. (PMID: 29681949)
Oncotarget. 2015 Feb 10;6(4):2315-30. (PMID: 25537513)
Nat Med. 2002 Sep;8(9):979-86. (PMID: 12185362)
Mol Cancer Res. 2018 Dec;16(12):1952-1964. (PMID: 30082484)
Sci Rep. 2020 Jan 20;10(1):641. (PMID: 31959810)
Front Oncol. 2019 Oct 24;9:1104. (PMID: 31709180)
Cell Commun Signal. 2018 Jan 08;16(1):3. (PMID: 29329585)
Biochem Biophys Res Commun. 2017 May 13;486(4):1069-1076. (PMID: 28373070)
Cell Oncol (Dordr). 2020 Apr;43(2):155-176. (PMID: 31392521)
Cell Stem Cell. 2007 Nov;1(5):555-67. (PMID: 18371393)
J Steroid Biochem Mol Biol. 2015 Apr;148:148-55. (PMID: 25445919)
Cell. 2019 Jan 10;176(1-2):98-112.e14. (PMID: 30633912)
Oncol Rep. 2015 Nov;34(5):2731-7. (PMID: 26351897)
J Steroid Biochem Mol Biol. 2017 Oct;173:122-129. (PMID: 27923595)
Biochim Biophys Acta Mol Basis Dis. 2018 Jan;1864(1):89-101. (PMID: 29038050)
BMC Complement Altern Med. 2016 Mar 31;16:113. (PMID: 27036550)
Int J Mol Sci. 2018 Nov 30;19(12):. (PMID: 30513573)
Oncotarget. 2017 May 23;8(21):35205-35221. (PMID: 28445132)
J Cell Biochem. 2018 May;119(5):4134-4141. (PMID: 29243835)
Biochem Soc Trans. 2017 Feb 8;45(1):223-228. (PMID: 28202676)
J Biol Chem. 2015 Jul 17;290(29):17690-709. (PMID: 26018078)
Oncogene. 2019 May;38(22):4412-4424. (PMID: 30742096)
Molecules. 2019 Sep 05;24(18):. (PMID: 31492037)
Exp Oncol. 2017 Sep;39(3):203-211. (PMID: 28967645)
Oncogene. 2012 Mar 15;31(11):1354-65. (PMID: 21822303)
Cancer Prev Res (Phila). 2014 Jun;7(6):617-26. (PMID: 24691501)
Cold Spring Harb Perspect Med. 2013 Dec 01;3(12):a014381. (PMID: 24296349)
Stem Cell Res Ther. 2010 Dec 14;1(5):39. (PMID: 21156086)
Genes Cancer. 2010 Jun;1(6):629-40. (PMID: 21779462)
Mol Cancer. 2014 Sep 12;13:213. (PMID: 25216750)
Nat Commun. 2018 Feb 8;9(1):578. (PMID: 29422613)
Stem Cells. 2015 Aug;33(8):2381-90. (PMID: 25821200)
Cell Biol Toxicol. 2019 Apr;35(2):161-177. (PMID: 30220009)
Front Oncol. 2014 Dec 04;4:345. (PMID: 25538890)
Neoplasia. 2015 Jun;17(6):497-508. (PMID: 26152358)
Nat Rev Clin Oncol. 2015 Aug;12(8):445-64. (PMID: 25850553)
Cell. 2010 Jan 8;140(1):62-73. (PMID: 20074520)
Science. 2018 Aug 17;361(6403):. (PMID: 30026314)
Nutr Cancer. 2016 Oct;68(7):1202-9. (PMID: 27552186)
Biochem Biophys Res Commun. 2011 Aug 12;411(4):786-91. (PMID: 21798248)
Cancer Res. 2008 Oct 1;68(19):7711-7. (PMID: 18829523)
Oncogene. 2019 May;38(21):4047-4060. (PMID: 30705400)
Int J Biochem Cell Biol. 2017 Aug;89:85-94. (PMID: 28600142)
Breast Cancer. 2014 Jan;21(1):96-101. (PMID: 22528804)
Am J Pathol. 2003 Oct;163(4):1539-49. (PMID: 14507660)
Onco Targets Ther. 2018 Dec 06;11:8773-8781. (PMID: 30584335)
Carcinogenesis. 2014 Jan;35(1):2-13. (PMID: 23955540)
Oncotarget. 2016 Jan 5;7(1):580-92. (PMID: 26556862)
Genes Dev. 1995 Jul 15;9(14):1679-93. (PMID: 7622033)
Sci Rep. 2017 Oct 23;7(1):13856. (PMID: 29062075)
J Steroid Biochem Mol Biol. 1996 Jul;58(4):367-76. (PMID: 8903420)
Cell Chem Biol. 2017 Jul 20;24(7):833-844.e9. (PMID: 28648376)
Mol Cancer. 2017 Mar 7;16(1):57. (PMID: 28270211)
Breast Cancer Res Treat. 2019 May;175(1):77-90. (PMID: 30725231)
Exp Cell Res. 2018 Sep 15;370(2):444-453. (PMID: 29981340)
J Clin Invest. 2014 Dec;124(12):5453-65. (PMID: 25384215)
Oncotarget. 2015 Mar 20;6(8):6326-40. (PMID: 25811972)
Cancer Res. 2006 Jun 15;66(12):6063-71. (PMID: 16778178)
Cancer Prev Res (Phila). 2014 Jul;7(7):738-47. (PMID: 24824039)
Phytomedicine. 2019 May;58:152740. (PMID: 31005718)
Cancer Med. 2018 Oct;7(10):5130-5144. (PMID: 30239174)
Front Oncol. 2018 Mar 29;8:92. (PMID: 29651407)
Onco Targets Ther. 2018 Sep 06;11:5559-5567. (PMID: 30233217)
Oncogene. 2017 Jun 1;36(22):3193-3206. (PMID: 28218902)
Nat Rev Cancer. 2004 Jan;4(1):61-70. (PMID: 14708026)
Oncotarget. 2016 Dec 13;7(50):83278-83293. (PMID: 27829216)
Clin Breast Cancer. 2013 Feb;13(1):7-15. (PMID: 23127340)
Mediators Inflamm. 2014;2014:141747. (PMID: 24891760)
Biochem Pharmacol. 1992 Aug 18;44(4):693-702. (PMID: 1324683)
Cells. 2018 Nov 10;7(11):. (PMID: 30423843)
Cancer Res. 2010 Jun 1;70(11):4624-33. (PMID: 20484027)
Stem Cells Int. 2017;2017:5619472. (PMID: 28473858)
J Vis Exp. 2015 Mar 22;(97):. (PMID: 25867607)
Oncotarget. 2014 Nov 15;5(21):10803-15. (PMID: 25301732)
Cancer Cell. 2019 Jan 14;35(1):17-32.e6. (PMID: 30645973)
Cancer Res. 2016 Apr 1;76(7):2013-2024. (PMID: 26787836)
Br J Cancer. 2018 Dec;119(12):1495-1507. (PMID: 30482914)
Oncotarget. 2015 Sep 29;6(29):27923-37. (PMID: 26314846)
PLoS One. 2009 Dec 21;4(12):e8377. (PMID: 20027313)
Breast Cancer Res Treat. 2016 Jul;158(1):29-41. (PMID: 27306423)
J Virol. 1978 Nov;28(2):600-10. (PMID: 214581)
Exp Ther Med. 2017 May;13(5):2463-2467. (PMID: 28565864)
Breast Cancer Res. 2008;10(2):R25. (PMID: 18366788)
Nature. 2001 Nov 1;414(6859):105-11. (PMID: 11689955)
Oncotarget. 2015 Feb 28;6(6):3553-62. (PMID: 25708684)
Cancers (Basel). 2019 May 24;11(5):. (PMID: 31137748)
Gene. 2019 Jun 20;702:46-55. (PMID: 30898700)
EMBO Mol Med. 2014 Jan;6(1):66-79. (PMID: 24178749)
Cancer Res. 2016 Jan 15;76(2):440-52. (PMID: 26676751)
Anticancer Res. 2012 Jan;32(1):249-57. (PMID: 22213313)
Mol Cancer. 2018 Mar 6;17(1):70. (PMID: 29510731)
Immunopharmacol Immunotoxicol. 2011 Jun;33(2):241-9. (PMID: 20929432)
Breast Cancer Res. 2008;10(1):R10. (PMID: 18241344)
Nat Commun. 2018 Mar 9;9(1):1024. (PMID: 29523784)
Tumour Biol. 2017 Oct;39(10):1010428317729933. (PMID: 29072131)
Cell. 2010 Oct 15;143(2):313-24. (PMID: 20946988)
Cell Death Differ. 2005 Oct;12(10):1297-309. (PMID: 15905882)
Biochim Biophys Acta. 2014 Nov;1842(11):2087-95. (PMID: 25068817)
Cell. 2009 Sep 4;138(5):822-9. (PMID: 19737509)
Nat Rev Mol Cell Biol. 2016 Nov;17(11):722-735. (PMID: 27507209)
Oncogene. 2019 May;38(20):3765-3780. (PMID: 30262865)
Acta Biochim Biophys Sin (Shanghai). 2018 Jan 1;50(1):121-132. (PMID: 29190313)
Oncotarget. 2019 Mar 12;10(21):2068-2085. (PMID: 31007849)
Anticancer Res. 2010 Oct;30(10):3853-67. (PMID: 21036696)
Cancer Res. 2009 Jun 1;69(11):4810-7. (PMID: 19458072)
Cell Rep. 2018 May 15;23(7):2095-2106. (PMID: 29768207)
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3940-4. (PMID: 10097142)
Oncotarget. 2016 Jul 19;7(29):45608-45621. (PMID: 27323810)
Exp Oncol. 2015 Mar;37(1):58-63. (PMID: 25804234)
J Cell Mol Med. 2019 Sep;23(9):5994-6004. (PMID: 31273952)
Cell Cycle. 2013 Jul 1;12(13):2042-50. (PMID: 23759596)
Cell Stem Cell. 2014 Mar 6;14(3):275-91. (PMID: 24607403)
Sci Rep. 2017 Aug 23;7(1):9170. (PMID: 28835684)
Anticancer Drugs. 2015 Jun;26(5):487-97. (PMID: 25603020)
Oncogene. 2013 May 2;32(18):2261-72, 2272e.1-11. (PMID: 22733132)
Sci Rep. 2016 Jan 11;6:18772. (PMID: 26752044)
Cold Spring Harb Perspect Biol. 2012 May 01;4(5):. (PMID: 22550229)
Stem Cells. 2016 Jan;34(1):55-66. (PMID: 26418365)
Breast Cancer Res Treat. 2020 Feb;179(3):615-629. (PMID: 31784862)
Semin Cancer Biol. 2018 Oct;52(Pt 2):94-106. (PMID: 29752993)
Stem Cells Int. 2016;2016:1740936. (PMID: 27418931)
Am J Transl Res. 2019 Dec 15;11(12):7310-7323. (PMID: 31934280)
Breast Cancer. 2018 Nov;25(6):706-716. (PMID: 29948958)
Int J Oncol. 2015 Mar;46(3):1141-8. (PMID: 25544568)
Neoplasia. 2008 Dec;10(12):1433-43. (PMID: 19048122)
Oncologist. 2009 Apr;14(4):320-68. (PMID: 19346299)
Cancer Res. 2007 Sep 15;67(18):8643-52. (PMID: 17875704)
Stem Cells Transl Med. 2015 Sep;4(9):1033-43. (PMID: 26136504)
Cancer Manag Res. 2018 Nov 16;10:5767-5784. (PMID: 30510447)
Stem Cells. 2010 May;28(5):885-93. (PMID: 20333750)
Oncotarget. 2017 May 30;8(22):36305-36318. (PMID: 28422735)
Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):960-5. (PMID: 26677875)
Cell Death Differ. 2018 Nov;25(10):1781-1795. (PMID: 29511337)
Breast Cancer Res. 2018 Nov 20;20(1):137. (PMID: 30454027)
Oncol Lett. 2018 Jun;15(6):8749-8755. (PMID: 29805613)
Cancer Lett. 2016 Aug 28;379(1):60-9. (PMID: 27238569)
Sci Rep. 2018 May 9;8(1):7329. (PMID: 29743726)
JAMA Netw Open. 2020 Jan 3;3(1):e1918160. (PMID: 31899528)
Oncogene. 2001 Apr 26;20(18):2264-72. (PMID: 11402321)
Cancer Res. 2018 Apr 1;78(7):1657-1671. (PMID: 29358169)
Sci Rep. 2015 Jul 23;5:12465. (PMID: 26202299)
Cells. 2019 Apr 25;8(4):. (PMID: 31027259)
Signal Transduct Target Ther. 2020 Feb 7;5(1):8. (PMID: 32296030)
J Exp Clin Cancer Res. 2018 Dec 12;37(1):311. (PMID: 30541574)
Cancer Lett. 2012 Aug 1;321(1):80-8. (PMID: 22381696)
Breast Cancer Res. 2007;9(1):R6. (PMID: 17239243)
Dev Cell. 2014 Aug 11;30(3):295-308. (PMID: 25117682)
Cell Death Differ. 2017 Jan;24(1):155-166. (PMID: 27740625)
Int J Cancer. 2016 Jun 1;138(11):2570-8. (PMID: 26559373)
Grant Information :
R01 CA127645 United States CA NCI NIH HHS; R01 AT007036 United States AT NCCIH NIH HHS; P30 ES005022 United States ES NIEHS NIH HHS
Contributed Indexing :
Keywords: breast cancer*; cancer stem cells*; differentiation*; pluripotency*
Substance Nomenclature :
0 (Antineoplastic Agents)
0 (Transcription Factors)
Entry Date(s) :
Date Created: 20210111 Date Completed: 20210322 Latest Revision: 20210322
Update Code :
20210323
PubMed Central ID :
PMC7855917
DOI :
10.1002/mc.23277
PMID :
33428807
Czasopismo naukowe
The evolving concept that cancer stem cells (CSCs) are the driving element in cancer development, evolution and heterogeneity, has overridden the previous model of a tumor consisting of cells all with similar sequentially acquired mutations and a similar potential for renewal, invasion and metastasis. This paradigm shift has focused attention on therapeutically targeting CSCs directly as a means of eradicating the disease. In breast cancers, CSCs can be identified by cell surface markers and are characterized by their ability to self-renew and differentiate, resist chemotherapy and radiation, and initiate new tumors upon serial transplantation in xenografted mice. These functional properties of CSCs are regulated by both intracellular and extracellular factors including pluripotency-related transcription factors, intracellular signaling pathways and external stimuli. Several classes of natural products and synthesized compounds have been studied to target these regulatory elements and force CSCs to lose stemness and/or terminally differentiate and thereby achieve a therapeutic effect. However, realization of an effective treatment for breast cancers, focused on the biological effects of these agents on breast CSCs, their functions and signaling, has not yet been achieved. In this review, we delineate the intrinsic and extrinsic factors identified to date that control or promote stemness in breast CSCs and provide a comprehensive compilation of potential agents that have been studied to target breast CSCs, transcription factors and stemness-related signaling. Our aim is to stimulate further study of these agents that could become the basis for their use as stand-alone treatments or components of combination therapies effective against breast cancers.
(© 2021 Wiley Periodicals LLC.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies